Teo, AndrewHasang, WinaRandall, Louise M.Unger, Holger WernerSiba, PeterMueller, IvoBrown, Graham V.Rogerson, Stephen John2016-02-042016-02-042015-05-261475-2875https://hdl.handle.net/2445/69241BACKGROUND: Regular anti-malarial therapy in pregnancy, a pillar of malaria control, may affect malaria immunity, with therapeutic implications in regions of reducing transmission. METHODS: Plasma antibodies to leading vaccine candidate merozoite antigens and opsonizing antibodies to endothelial-binding and placental-binding infected erythrocytes were quantified in pregnant Melanesian women receiving sulfadoxine-pyrimethamine (SP) with chloroquine taken once, or three courses of SP with azithromycin. RESULTS: Malaria prevalence was low. Between enrolment and delivery, antibodies to recombinant antigens declined in both groups (p < 0.0001). In contrast, median levels of opsonizing antibodies did not change, although levels for some individuals changed significantly. In multivariate analysis, the malaria prevention regimen did not influence antibody levels. CONCLUSION: Different preventive anti-malarial chemotherapy regimens used during pregnancy had limited impact on malarial-immunity in a low-transmission region of Papua New Guinea. TRIAL REGISTRATIONS: NCT01136850.8 p.application/pdfengcc by (c) Teo et al., 2015http://creativecommons.org/licenses/by/3.0/es/MalàriaPlasmodium falciparumImmunitatEmbaràsMalariaPlasmodium falciparumImmunityPregnancyinfo:eu-repo/semantics/article2016-02-02info:eu-repo/semantics/openAccess26006260